Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Monte Rosa Therapeutics Inc | GLUE | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.61 | 06:53:37 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.61 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.44 - 8.84 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 5.61 | USD |
Monte Rosa Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 281.36M | 50.15M | - | 0 | -135.35M | -2.70 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Monte Rosa Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLUE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.57 | 6.045 | 5.11 | 5.48 | 94,140 | 0.04 | 0.72% |
| 1 Month | 6.90 | 8.22 | 5.11 | 6.49 | 123,185 | -1.29 | -18.70% |
| 3 Months | 4.80 | 8.84 | 4.185 | 6.31 | 138,580 | 0.81 | 16.88% |
| 6 Months | 2.78 | 8.84 | 2.765 | 5.19 | 182,146 | 2.83 | 101.80% |
| 1 Year | 4.62 | 8.84 | 2.44 | 5.38 | 195,948 | 0.99 | 21.43% |
| 3 Years | 22.00 | 45.56 | 2.44 | 11.31 | 207,016 | -16.39 | -74.50% |
| 5 Years | 22.00 | 45.56 | 2.44 | 11.31 | 207,016 | -16.39 | -74.50% |
Monte Rosa Therapeutics Description
| Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. |
